NS Partners Ltd reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 30.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,141 shares of the medical research company’s stock after selling 8,493 shares during the period. NS Partners Ltd’s holdings in Amgen were worth $3,140,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in AMGN. Kentucky Retirement Systems purchased a new stake in shares of Amgen during the fourth quarter worth approximately $7,893,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of Amgen during the fourth quarter worth approximately $3,521,000. Searle & CO. purchased a new stake in shares of Amgen during the fourth quarter worth approximately $1,019,000. Opus Point Partners Management LLC boosted its stake in shares of Amgen by 2.3% in the fourth quarter. Opus Point Partners Management LLC now owns 18,743 shares of the medical research company’s stock worth $2,740,000 after buying an additional 421 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Amgen by 70.4% in the fourth quarter. Macquarie Group Ltd. now owns 227,254 shares of the medical research company’s stock worth $33,228,000 after buying an additional 93,895 shares in the last quarter. Hedge funds and other institutional investors own 79.53% of the company’s stock.
Shares of Amgen Inc. (AMGN) traded up 0.19% during midday trading on Friday, reaching $169.43. 1,571,584 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $174.48 and a 200 day moving average price of $167.49. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The company has a market cap of $123.63 billion, a P/E ratio of 15.43 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the prior year, the business posted $2.84 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. Equities research analysts forecast that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.71%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.
A number of analysts have commented on AMGN shares. Cowen and Company reiterated an “outperform” rating and issued a $209.00 price target on shares of Amgen in a research note on Wednesday, April 19th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $178.00 price target on shares of Amgen in a research note on Tuesday, April 25th. Robert W. Baird reiterated a “neutral” rating and issued a $165.00 price target on shares of Amgen in a research note on Friday, April 28th. Mizuho set a $195.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $186.64.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.